![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
ALK-Abelló A/S |
Information provided by: | ALK-Abelló A/S |
ClinicalTrials.gov Identifier: | NCT00535639 |
This trial is performed to assess the tolerability of the ALK Tree Tablet in patients with birch pollen induced allergy
Condition | Intervention | Phase |
Allergy |
Drug: Betula Verrucosa allergen extract |
Phase I |
MedlinePlus related topics: | Allergy |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Parallel Assignment |
Official Title: | A Randomised, Multiple Dose, Dose Escalation, Double-Blind, Placebo-Controlled Phase I Study Investigating the Safety of ALK Tree Tablet in Adult Subjects With Birch Pollen Induced Rhinoconjunctivitis (With/Without Asthma). |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | TT-01 |
First Received: | September 25, 2007 |
Last Updated: | February 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00535639 |
Health Authority: | Denmark: Danish Medicines Agency; Denmark: The Regional Committee on Biomedical Research Ethics |
|
|
![]() |